Lorlatinib
Overview
Lorlatinib is a third-generation anaplastic lymphoma kinase inhibitor designed to target specific genetic alterations in cancer cells, particularly ALK rearrangements. It works by inhibiting the ALK and ROS1 tyrosine kinases, which are involved in tumor cell proliferation and survival in certain types of non-small cell lung cancer. Lorlatinib has been specifically engineered to overcome resistance mutations that develop with earlier-generation ALK inhibitors and has the ability to penetrate the blood-brain barrier, making it effective in controlling central nervous system metastases. It is administered orally and is used in advanced or metastatic settings. Its targeted mechanism allows for selective inhibition of cancer growth while minimizing effects on normal cells, making it an important option in precision oncology for ALK-positive lung cancer.
Background and Date of Approval
Lorlatinib was developed as a next-generation ALK inhibitor to address resistance to earlier therapies in ALK-positive lung cancer. It received accelerated approval from the United States Food and Drug Administration on November 2, 2018 for patients with ALK-positive metastatic non-small cell lung cancer who had progressed on prior ALK inhibitor therapies. Subsequently, on March 3, 2021, the United States Food and Drug Administration granted regular approval and expanded its use as a first-line treatment for patients with metastatic ALK-positive non-small cell lung cancer. Regulatory approvals have also been granted in other regions, including approval by the European Commission on January 28, 2022 for use in untreated advanced ALK-positive non-small cell lung cancer based on Phase III clinical trial data demonstrating improved progression-free survival.
Uses
Lorlatinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer. It may be used as first-line therapy or in patients who have previously received one or more ALK inhibitors. It is particularly valuable in patients with central nervous system involvement due to its high intracranial activity.
Administration
Lorlatinib is administered orally, typically at a dose of 100 mg once daily. Treatment is continued until disease progression or unacceptable toxicity occurs. Dose modifications may be required based on adverse effects or patient tolerance. Regular clinical and laboratory monitoring is necessary during treatment.
Side Effects
Common side effects include edema, weight gain, fatigue, peripheral neuropathy, cognitive effects, mood changes, diarrhea, and cough. Laboratory abnormalities such as increased cholesterol and triglyceride levels are also frequently observed. These effects are generally manageable with dose adjustments and supportive care.
Warnings
Serious adverse events include central nervous system effects such as cognitive impairment, mood disorders, and seizures. Severe hyperlipidemia requiring medical management may occur. Interstitial lung disease or pneumonitis has been reported and may require treatment interruption. Cardiac effects such as atrioventricular block may also occur. Treatment should be discontinued or adjusted in cases of severe toxicity.
Precautions
Patients should undergo baseline assessment including lipid profile, liver function, and cardiac evaluation. Lorlatinib is known to interact with cytochrome P450 enzymes, particularly CYP3A, and may interact with other medications metabolized through these pathways. Concomitant use with strong CYP3A inducers or inhibitors should be carefully managed. Monitoring for central nervous system effects and metabolic changes is essential during therapy.
Expert Tips
Lorlatinib is best suited for patients with confirmed ALK-positive lung cancer, particularly those with resistance to earlier ALK inhibitors or brain metastases. Baseline and periodic lipid monitoring is essential due to high incidence of hyperlipidemia. Clinicians should counsel patients regarding potential cognitive and mood changes. Dose adjustments should be made promptly in response to adverse effects. Multidisciplinary coordination with oncology specialists is recommended for optimal management.